191 related articles for article (PubMed ID: 24317129)
1. Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement.
Girnius S; Seldin DC; Meier-Ewert HK; Sloan JM; Quillen K; Ruberg FL; Berk JL; Doros G; Sanchorawala V
Bone Marrow Transplant; 2014 Mar; 49(3):434-9. PubMed ID: 24317129
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Propylene Glycol-Free Melphalan in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Results of a Phase II Study.
Sarosiek S; Lee MH; Doros G; Edwards CV; Quillen K; Brauneis D; Shelton AC; Sanchorawala V; Sloan JM
Transplant Cell Ther; 2023 Nov; 29(11):695.e1-695.e7. PubMed ID: 37607644
[TBL] [Abstract][Full Text] [Related]
3. High-Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to Immunoglobulin Light-Chain Amyloidosis and Monoclonal Immunoglobulin Deposition Disease.
Batalini F; Econimo L; Quillen K; Sloan JM; Sarosiek S; Brauneis D; Havasi A; Stern L; Dember LM; Sanchorawala V
Biol Blood Marrow Transplant; 2018 Jan; 24(1):127-132. PubMed ID: 28865972
[TBL] [Abstract][Full Text] [Related]
4. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
[TBL] [Abstract][Full Text] [Related]
5. A second course of high-dose melphalan and auto-SCT for the treatment of relapsed AL amyloidosis.
Quillen K; Seldin DC; Finn KT; Sanchorawala V
Bone Marrow Transplant; 2011 Jul; 46(7):976-80. PubMed ID: 20956955
[TBL] [Abstract][Full Text] [Related]
6. High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement.
Madan S; Kumar SK; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Dingli D; Rajkumar SV; Hogan WJ; Leung N; Grogan M; Gertz MA
Blood; 2012 Feb; 119(5):1117-22. PubMed ID: 22147893
[TBL] [Abstract][Full Text] [Related]
7. Autologous stem cell transplantation for AL amyloidosis: adjustment of melphalan dose by factors including BNP.
Hayashi T; Ikeda H; Igarashi T; Maruyama Y; Aoki Y; Nojima M; Ishida T; Shinomura Y
Int J Hematol; 2014 Dec; 100(6):554-8. PubMed ID: 25281404
[TBL] [Abstract][Full Text] [Related]
8. Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial.
Sanchorawala V; Brauneis D; Shelton AC; Lo S; Sun F; Sloan JM; Quillen K; Seldin DC
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1445-51. PubMed ID: 25858810
[TBL] [Abstract][Full Text] [Related]
9. Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis.
Girnius S; Seldin DC; Skinner M; Finn KT; Quillen K; Doros G; Sanchorawala V
Ann Hematol; 2010 Jun; 89(6):579-84. PubMed ID: 20012043
[TBL] [Abstract][Full Text] [Related]
10. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial.
Sanchorawala V; Wright DG; Seldin DC; Falk RH; Finn KT; Dember LM; Berk JL; Quillen K; Anderson JJ; Comenzo RL; Skinner M
Bone Marrow Transplant; 2004 Feb; 33(4):381-8. PubMed ID: 14676787
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation.
Sanchorawala V; Skinner M; Quillen K; Finn KT; Doros G; Seldin DC
Blood; 2007 Nov; 110(10):3561-3. PubMed ID: 17673601
[TBL] [Abstract][Full Text] [Related]
12. [Clinical analysis of autologous stem cell transplantation for nine cases of cardiac amyloidosis].
Ogura M; Sekine R; Nishiyama S; Abe Y; Iizuka H; Kusaka S; Nakagawa Y; Suzuki K
Rinsho Ketsueki; 2012 Jul; 53(7):710-5. PubMed ID: 22975774
[TBL] [Abstract][Full Text] [Related]
13. Microbiologically documented infections in patients undergoing high-dose melphalan and autologous stem cell transplantation for the treatment of light chain amyloidosis.
Taimur S; Nader C; Lloyd-Travaglini C; Seldin DC; Sanchorawala V
Transpl Infect Dis; 2013 Apr; 15(2):187-94. PubMed ID: 23279695
[TBL] [Abstract][Full Text] [Related]
14. Modified High-Dose Melphalan and Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis.
Nguyen VP; Landau H; Quillen K; Brauneis D; Shelton AC; Mendelson L; Rahman H; Sloan JM; Sarosiek S; Sanchorawala V
Biol Blood Marrow Transplant; 2018 Sep; 24(9):1823-1827. PubMed ID: 29933072
[TBL] [Abstract][Full Text] [Related]
15. Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis.
Landau H; Smith M; Landry C; Chou JF; Devlin SM; Hassoun H; Bello C; Giralt S; Comenzo RL
Leukemia; 2017 Jan; 31(1):136-142. PubMed ID: 27560108
[TBL] [Abstract][Full Text] [Related]
16. Plerixafor-augmented peripheral blood stem cell mobilization in AL amyloidosis with cardiac involvement: a case series.
Lee SY; Sanchorawala V; Seldin DC; Mark Sloan J; Andrea N; Quillen K
Amyloid; 2014 Sep; 21(3):149-53. PubMed ID: 24779777
[TBL] [Abstract][Full Text] [Related]
17. Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.
Cowan AJ; Klippel ZK; Stevenson PA; Hyun TS; Tuazon S; Becker PS; Green DJ; Holmberg LA; Coffey DG; Gopal AK; Libby EN
Amyloid; 2016 Dec; 23(4):254-259. PubMed ID: 27879147
[TBL] [Abstract][Full Text] [Related]
18. High-dose therapy with auto-SCT is feasible in high-risk cardiac amyloidosis.
Kongtim P; Qazilbash MH; Shah JJ; Hamdi A; Shah N; Bashir Q; Wang M; Champlin R; Manasanch EE; Weber D; Orlowski RZ; Parmar S
Bone Marrow Transplant; 2015 May; 50(5):668-72. PubMed ID: 25730192
[TBL] [Abstract][Full Text] [Related]
19. Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25-year longitudinal study.
Gustine JN; Staron A; Szalat RE; Mendelson LM; Joshi T; Ruberg FL; Siddiqi O; Gopal DM; Edwards CV; Havasi A; Kaku M; Lau KHV; Berk JL; Sloan JM; Sanchorawala V
Am J Hematol; 2022 Sep; 97(9):1189-1199. PubMed ID: 35731907
[TBL] [Abstract][Full Text] [Related]
20. Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial.
Huang X; Wang Q; Chen W; Zeng C; Chen Z; Gong D; Zhang H; Liu Z
BMC Med; 2014 Jan; 12():2. PubMed ID: 24386911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
